ClinicalTrials.gg
CompletedNCT00847483XLTUpdated Feb 2, 2021

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

A Phase 4 interventional study of latanoprost 0.005% ophthalmic solution and Travoprost 004% sterile ophthalmic solution in Glaucoma and Ocular Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 40 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing latanoprost in Glaucoma — 2 open to participants now, 2 under way, none of them phase 3. Latanoprost · Glaucoma.

Enrollment
3rd of 44
375 · median 56
Started
2002
with 1 other
Phase 4
18 of 46
1 open now
Registered
23rd of 46
by date
Lead sponsor
4 of 46
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 46 studies testing latanoprost in Glaucoma, this one is the 3rd largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2002, is one of 18 in phase 4, and was the 23rd registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

2 of the 46 studies testing latanoprost in Glaucoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About latanoprost

Latanoprost: first FDA approval 1996 (XALATAN), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing latanoprost in Glaucoma, or all of them as a file.
02

Study summary

Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Keywords

  • glaucoma
  • ocular hypertension
  • latanoprost
  • travoprost
  • bimatoprost
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral or bilateral primary open angle glaucoma (POAG), exfoliative glaucoma, pigmentary glaucoma or ocular hypertension (glaucoma is defined as either visual fields defect or glaucomatous changes of the optic nerve head in association with elevated intraocular pressure. Ocular hypertension is defined as IOP ≥ 21 mmHg at diagnosis).
  • Is currently receiving (at the screen visit) or has received topical monotherapy or dual therapy (within the past 6 months) for POAG or ocular hypertension.
  • Required are 4 weeks for -adrenergic antagonists, prostaglandin analogues (including latanoprost, unoprostone, travoprost and bimatoprost) and 2 weeks for adrenergic agonists, and 5 days for cholinergic agonists and carbonic anhydrase inhibitors, prior to the baseline visit.
  • Mean 8 AM IOP ≥ 23 mmHg at the baseline visit for all patients. Patients should be assigned treatment only after the 8 PM IOP is obtained.
  • Visual acuity (best corrected) equal to or better than 20/200 (Snellen). ETDRS charts may be used and converted to Snellen units.
  • : Signed Informed Consent is obtained at the screen visit.
  • Able to adhere to treatment/visit planUnilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
  • Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilaterally must fulfill eligibility criteria for both eyes.)
  • IOP of 22mmHg or higher obtained during the pre-study period.

Exclusion criteria

Exclusion Criteria:

Ocular conditions

  • Closed/barely open anterior chamber angle or history of acute angle closure. (Patients who are diagnosed with POAG after a successful peripheral iridotomy may be enrolled).
  • History of (Argon Laser Trabeculoplasty) within 3 months prior to the screen visit (the unlasered eye may be enrolled as the study eye).
  • History of any ocular filtering surgical intervention (the unfiltered eye may be enrolled as the study eye).
  • Ocular surgery (on the globe of the eye only), or inflammation/infection within 3 months prior to screen visit. (Applies to both fellow and study eyes.)
  • to benzalkonium chloride or to any other component in latanoprost (Xalatan), travoprost (Travatan) or bimatoprost (Lumigan).
  • Other abnormal ocular conditions or symptoms preventing the patient from entering the study, in the investigator's clinical judgement.

Other conditions

  • Use of systemic medication known to affect IOP (i.e., alpha-adrenergic agonists, beta-adrenergic antagonists, calcium channel blockers, ACE inhibitors and/or angiotensin II receptor blockers, or ), unless the patient and the medication dosage have been stable for three months prior to the screen visit and the dosage is not expected to change during the study.

Women

  • Women of (WOCBP) who are not using methods. Women of childbearing potential are defined as women who are not surgically sterile or not (at least 12 months without a menstrual period). Contraception is defined as abstinence, having a vasectomized partner, or the ongoing use of approved oral, injectable or implanted contraceptives, a barrier method, or an IUD.
  • Pregnancy. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at the screen visit and baseline visit.
  • Nursing mothers General
  • Use of any medication within 30 days prior to screen visit.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
375 participants (actual)

Study arms

  • Active comparator
    Latanoprost

    Drug: latanoprost 0.005% ophthalmic solution

  • Active comparator
    Travoprost

    Drug: Travoprost 004% sterile ophthalmic solution

  • Active comparator
    Bimatoprost

    Drug: Bimatoprost .03% sterile ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. To compare the IOP reducing effect of latanoprost (Xalatan) versus travoprost (Travatan) versus bimatoprost (Lumigan) over a twelve-week period.

    Time frame: 12 weeks

  2. The mean change since baseline of Week 12 IOP measured at the time of peak (8:00AM) drug effect.

    Time frame: 12 weeks

Secondary outcomes

  1. To study the safety variables within and between all treatment groups over 12 weeks

    Time frame: 12 weeks

  2. The mean change since baseline of Week 12 IOP measured at the time of trough (8:00PM) drug effect. The mean percentage change since baseline of diurnal IOP at Week 12.

    Time frame: 12 weeks

  3. The mean change since baseline of Week 12 IOP measured at the times of peak (8:00AM) and trough (8:00PM) drug effects evaluated by race. The percentage of patient withdrawals from the study

    Time frame: 12 weeks

07

Study locations

40 sites
  • Pfizer Investigational Site
    Bellflower, California 90706, United States
  • Pfizer Investigational Site
    Inglewood, California 90301, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    San Diego, California 92116, United States
  • Pfizer Investigational Site
    San Francisco, California 94115, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32610, United States
  • Pfizer Investigational Site
    Lakeland, Florida 33805, United States
  • Pfizer Investigational Site
    Ormond Beach, Florida 32174, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30339, United States
  • Pfizer Investigational Site
    Bloomingdale, Illinois 60108, United States
  • Pfizer Investigational Site
    Evansville, Indiana 47710, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40207, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40217, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 771104, United States
  • Pfizer Investigational Site
    Bangor, Maine 04401, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64111, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64114, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68198-5540, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89104, United States
  • Pfizer Investigational Site
    Bloomfield, New Jersey 07003, United States
  • Pfizer Investigational Site
    Willingboro, New Jersey 08046, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28210, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Streetsboro, Ohio 44241, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74104, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29412, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29414, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29425, United States
  • Pfizer Investigational Site
    Maryville, Tennessee 37803, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    El Paso, Texas 79902, United States
  • Pfizer Investigational Site
    Houston, Texas 77025, United States
  • Pfizer Investigational Site
    Layton, Utah 84041, United States
  • Pfizer Investigational Site
    Norfolk, Virginia 23505, United States
  • Pfizer Investigational Site
    Norfolk, Virginia 23507, United States
  • Pfizer Investigational Site
    Virginia Beach, Virginia 23456, United States
  • Pfizer Investigational Site
    Wenatchee, Washington 98801, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2002, a primary completion of Aug 2002 and a completion of Aug 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2009
First posted
Feb 19, 2009
Start
Jan 2002
Primary completionActual
Aug 2002
CompletionActual
Aug 2002
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00847483
Responsible party
Sponsor
First posted
Feb 19, 2009
Start date
Jan 2002
Primary completion
Aug 2002
Completion
Aug 2002
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Latanoprost · Travoprost · Bimatoprost

Start the discussion